Phenotypic characterization of CB-LCLs
Cell type . | CD77 . | CD38 . | Bcl-6 . | LMP1 . | LMP2A . | EBNA2 . |
|---|---|---|---|---|---|---|
| CD77+ B cells | 3/3 | 1/1* | ND* | ND | ND | ND |
| PB-LCLs | 1/3† | 3/3 | 0/3 | 3/3 | 2/2 | 3/3 |
| CB-LCLs | 3/8† | 8/8 | 0/7 | 7/7 | 6/6 | 7/7 |
Cell type . | CD77 . | CD38 . | Bcl-6 . | LMP1 . | LMP2A . | EBNA2 . |
|---|---|---|---|---|---|---|
| CD77+ B cells | 3/3 | 1/1* | ND* | ND | ND | ND |
| PB-LCLs | 1/3† | 3/3 | 0/3 | 3/3 | 2/2 | 3/3 |
| CB-LCLs | 3/8† | 8/8 | 0/7 | 7/7 | 6/6 | 7/7 |
Monoclonal CB-LCLs were analyzed for expression of CD77 and CD38 by flow cytometry; for expression of Bcl-6, LMP1, and EBNA2, by immunofluorescence staining on cytospins; and for expression of LMP2A, by Western blot analysis. As a control, LCLs established from peripheral blood B cells were also analyzed. The number of positive samples per samples analyzed is indicated.
ND indicates not determined.
The expression of CD38 and Bcl-6 by CD77+ GC B cells is known from the literature8,32
CD77 is expressed in the positively scored cell lines at low levels